PMID- 22422427
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20121002
LR  - 20240330
IS  - 1869-6961 (Electronic)
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Linking)
VI  - 3
IP  - 1
DP  - 2012 Nov
TI  - A review of exenatide: optimizing glycemic control and associated cardiovascular 
      risk factors in type 2 diabetes.
PG  - 1-16
LID - 10.1007/s13300-012-0003-x [doi]
LID - 3
AB  - Type 2 diabetes mellitus (T2DM) is a well-recognized risk factor for the 
      development of cardiovascular disease. With an increasing prevalence of obesity, 
      this risk has increased further. Management of T2DM in obese patients is 
      particularly challenging as treatment with the majority of glucose-lowering 
      agents results in weight gain. Thus, the development of a therapeutic option 
      which could improve glycemic control without weight gain or hypoglycemia, such as 
      the glucagon-like peptide-1 (GLP-1) analog exenatide, is a welcome addition to 
      the currently available therapies in the management of T2DM. With recognition and 
      better understanding of the role of incretin hormones in T2DM, exenatide was 
      developed and introduced into clinical practice in 2005. Both randomized 
      controlled trials and retrospective observational studies have shown that 
      treatment with exenatide not only improves glycemic control, with a low risk of 
      hypoglycemia, but also results in concurrent weight loss and the additional 
      benefit of improvement in cardiovascular risk factors. This article will provide 
      an overview of both short- and long-acting exenatide in the management of T2DM 
      and associated cardiovascular risk factors.
FAU - Htike, Zin Z
AU  - Htike ZZ
AD  - Department of Diabetes and Endocrinology, Leicester Royal Infirmary, University 
      Hospitals of Leicester NHS Trust, Leicester, UK.
FAU - Khunti, Kamlesh
AU  - Khunti K
FAU - Davies, Melanie
AU  - Davies M
LA  - eng
PT  - Journal Article
DEP - 20120316
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC3508112
EDAT- 2012/03/17 06:00
MHDA- 2012/03/17 06:01
PMCR- 2012/03/16
CRDT- 2012/03/17 06:00
PHST- 2011/12/02 00:00 [received]
PHST- 2012/03/17 06:00 [entrez]
PHST- 2012/03/17 06:00 [pubmed]
PHST- 2012/03/17 06:01 [medline]
PHST- 2012/03/16 00:00 [pmc-release]
AID - 3 [pii]
AID - 10.1007/s13300-012-0003-x [doi]
PST - ppublish
SO  - Diabetes Ther. 2012 Nov;3(1):1-16. doi: 10.1007/s13300-012-0003-x. Epub 2012 Mar 
      16.